Pharmacokinetic study of busulfan in allogeneic hematopoietic stem cell transplantation for patients with myeloid malignancies using once daily intravenous busulfan and cyclophosphamide as conditioning regime
Phase 2
- Conditions
- acute myeloid leukemia(AML) myelodysplastic syndrome(MDS) chronic myelogenous leukemia(CML)
- Registration Number
- JPRN-UMIN000009767
- Lead Sponsor
- Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Patients who withdraw the consent to participate in this study (2) Patients who are considered as inappropriate to register by attending physicians
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of patients who reach the targeted AUC range of busulfan after first and fourth dose
- Secondary Outcome Measures
Name Time Method Relationship between pharmacokinetics of busulfan and adverse events